Executives from six US and EU biotechnology companies who spoke with Scrip Intelligence agreed that it's great to commercialize novel therapies without a partner and retain all financial rewards, but for any biotech firm that's looking for a deep-pocketed collaborator, now is a good time to be negotiating deals.
The biotech executives took some time off from meeting with investors during the 33rd Annual JP Morgan Healthcare Conference from...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
